Tutti gli studi
Attivo ma non reclutanteOSSERVAZIONALE

Observatory of Patients With Haemophilia B Treated by IdElvion®

This study, called OrPHEe, is looking at how well a medicine called Idelvion® works for people with haemophilia B in France. Haemophilia B is a bleeding disorder where the blood doesn't clot properly due to a missing blood factor called Factor IX (FIX). Doctors already know Idelvion® helps, as shown in previous studies. This new study is observing patients in their normal lives to see how the treatment performs daily. It collects information on whether the medicine continues to prevent bleeds and if it’s safe, helping to understand its real-world benefits for patients.

A colpo d'occhio

Stato
Attivo ma non reclutante
Sponsor
CSL Behring
Obiettivo di iscrizione
222
Inizio
03 Dic 2021
Completamento stimato
01 Dic 2027

Di cosa tratta questo studio?

This study, called OrPHEe, is for people in France who have haemophilia B and are treated with a medicine called Idelvion®. Haemophilia B is a condition where your blood doesn't clot as it should, making you more likely to bleed. This happens because you don't have enough of a special protein in your blood called Factor IX (FIX).

Treatments for haemophilia B involve giving you the missing Factor IX. Idelvion® is a specific type of Factor IX treatment. Previous studies have already shown that Idelvion® is helpful for children and adults with haemophilia B, whether they use it to prevent bleeds regularly (called prophylaxis), for periods when they have a higher risk of bleeding, or to treat bleeds when they happen. It has also been shown to be useful around surgery.

The main goal of this current study is to simply observe patients in their daily lives. By doing this, doctors want to gather more information to confirm that Idelvion® continues to be effective in preventing bleeding episodes and is safe for patients in real-world situations. This type of study is important because it adds to our understanding of how medicines work outside of very controlled clinical trials.

Punti chiave

  • This study looks at how Idelvion® works for people with haemophilia B in their normal lives.
  • It aims to confirm the medicine's effectiveness and safety, based on real-world experiences.
  • You would continue your Idelvion® treatment as usual, with no new medicines involved.
  • Participation helps gather important information to understand and improve care for haemophilia B patients.
  • This study is currently recruiting patients in France.

Chi può essere idoneo?

To join this study, people must have haemophilia B and be currently using, or have previously used, Idelvion®. This could be for regular treatment to prevent bleeds, to treat bleeds when they happen, or for short periods around surgery or higher risk.

Taking part is voluntary. You (or your parents, if you're under 18) must agree after reading about the study. It's important that you don't have certain types of antibodies (special proteins) against Factor IX in your blood when you join.

There are also reasons why someone couldn't join. You can't take part if you (or your legal representative) don't want to. Also, if your doctor knows that Idelvion® isn't suitable for you (for example, if you have allergic reactions to Factor IX or hamster proteins), you wouldn't be able to participate. Lastly, if you're already in another study where you're trying a new medicine, you can't be in this one too.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. I have been diagnosed with haemophilia B.
  2. I am currently using or have used Idelvion® for my treatment.
  3. I (or my parents if I'm under 18) would agree to take part after getting information.
  4. My doctor has not said I have any allergies to Idelvion® or similar medicines.
  5. I am not currently taking part in another study testing a new medicine.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

This study is an 'observational' study. This means you would continue to receive your Idelvion® treatment as prescribed by your doctor, just as you normally would. The study isn't asking you to take a new or different medicine. Doctors will simply record information about your health and how your Idelvion® treatment is working during your usual clinic visits. There are no extra tests or visits specifically for this study. The total duration of your participation would depend on how long you remain on Idelvion® and your doctor continues to collect this information.

Rischi e benefici potenziali

The main benefit of this study is that it helps doctors and researchers understand more about how Idelvion® works for people with haemophilia B in their daily lives. This information can help improve care for others in the future. As this is an observational study, you are not asked to take new medication or undergo special procedures, so there are very few additional risks beyond your usual medical care. The most important right you have is to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (28)

  • CHU Amiens - Picardie
    Codice postale verificato
    Amiens, Francia
  • CH Annecy Genevois
    Codice postale verificato
    Annecy, France
  • CHRU Besançon
    Codice postale verificato
    Besançon, Francia
  • CHU Bordeaux - Hôpital Pellegrin
    Codice postale verificato
    Bordeaux, Francia
  • CHRU Brest
    Codice postale verificato
    Brest, Francia
  • CHU Caen
    Codice postale verificato
    Caen, France
  • CHU Clermont-Ferrand
    Codice postale verificato
    Clermont-Ferrand, France
  • CHU Dijon
    Codice postale verificato
    Dijon, Francia
  • Hôpital Simone Veil
    Codice postale verificato
    Eaubonne, France
  • CHU de Grenoble
    Codice postale verificato
    Grenoble, Francia
  • CRC-MHC Hôpital Kremlin Bicêtre
    Codice postale verificato
    Le Kremlin-Bicêtre, France
  • CH du Mans
    Codice postale verificato
    Le Mans, France

Domande comuni

What is haemophilia B?

Haemophilia B is a blood disorder where your blood doesn't clot properly because you have too little of a certain protein called Factor IX (FIX).

What is Idelvion®?

Idelvion® is a medication that provides the missing Factor IX protein to help your blood clot.

Will I take a new medicine in this study?

No, you will continue your Idelvion® treatment as prescribed by your doctor. This study just observes how it works in real life.

Per quanto tempo sarò nello studio?

Your participation will be tied to how long you are treated with Idelvion® and as long as your doctor is collecting this information as part of the study.

Do I have to live in France to participate?

Yes, this particular study is being done with patients in France.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.